3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
24
Lung Neoplasms
14
Neoplasm Metastasis
12
Carcinoma, Medullary
12
Neoplasms
10
Thyroid Neoplasms
8
Breast Neoplasms
8
Glioma
6
Prostatic Neoplasms
5
Glioblastoma
5
Squamous Cell Carcinoma of Head and Neck
4
Gliosarcoma
4
Colorectal Neoplasms
4
Brain Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Thyroid Cancer, Papillary
2
Stomach Neoplasms
2
Recurrence
2
Rectal Neoplasms
2
Pleural Effusion
2
Kidney Neoplasms
2
Familial medullary thyroid carcinoma
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Disease Progression
2
Interventions
3-Iodobenzylguanidine
8
Temozolomide
6
lutetium Lu 177 dotatate
5
gallium Ga 68 dotatate
4
anlotinib
4
Specimen Handling
4
Everolimus
4
Radiotherapy
3
Phenoxybenzamine
3
Magnetic Resonance Spectroscopy
3
Doxorubicin
3
6-fluorodopamine
3
olaparib
2
cabozantinib
2
belzutifan
2
Nivolumab
2
Ifosfamide
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Doxazosin
2
Dexmedetomidine
2
Capecitabine
2
Biopsy
2
Axitinib
2
3-fluorobenzylguanidine
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
veliparib
1
vatalanib
1
vandetanib
1
tipifarnib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pheochromocytoma
×
vandetanib
×
Clear all
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn